Maintenance of platelet inhibition during antiplatelet therapy

{
  "publication_number": "US10022391B2",
  "country": "US",
  "kind": "B2",
  "title": "Maintenance of platelet inhibition during antiplatelet therapy",
  "abstract": "A method for reducing or maintaining platelet inhibition in a patient by administering cangrelor prior to an invasive procedure is described. The method of this invention can be used for patients in need of antiplatelet therapy or at risk of thrombosis. The method can further be used in patients who were previously treated with long-acting platelet inhibitors without increasing the risk of excessive bleeding.",
  "claims": [
    "1. A method of maintaining P2Y 12 inhibition in a patient being treated with an oral P2Y 12 inhibitor who is in need of surgery, the method comprising: (a) discontinuing the treatment with the oral P2Y12 inhibitor; (b) administering intravenously a 4 μg/kg/min continuous infusion of cangrelor; and (c) continuing the administration of the continuous infusion for the longer of (i) at least two hours, or (ii) the duration of surgery.",
    "2. The method of claim 1, wherein the oral P2Y12 therapy is selected from the group consisting of clopidogrel, prasugrel, and ticagrelor.",
    "3. The method of claim 1, wherein the surgery is selected from percutaneous coronary intervention and coronary artery bypass grafting.",
    "4. The method of claim 1, further comprising wherein the cangrelor is administered as a bolus infusion in addition to the continuous infusion.",
    "5. The method of claim 4, wherein the bolus infusion is administered prior to the surgery.",
    "6. The method of claim 5, further comprising wherein the continuous infusion is administered immediately after the bolus infusion.",
    "7. The method of claim 4, wherein the bolus infusion is administered in less than one minute.",
    "8. The method of claim 1, wherein the continuous infusion is continued for a total duration of up to about 4 hours.",
    "9. The method of claim 1, wherein a second oral P2Y 12 inhibitor is administered after the discontinuation of the continuous infusion.",
    "10. The method of claim 9, wherein the second oral P2Y 12 inhibitor is selected from the group consisting of clopidogrel, prasugrel, and ticagrelor."
  ],
  "description_excerpt": "The instant invention relates to the field of platelet inhibition, and in particular to methods of maintaining or reducing platelet activity in patients undergoing an invasive procedure.\n\nAntiplatelet therapy has been shown to reduce clinical ischemic events and improve outcomes for acute coronary syndrome (ACS) patients. Currently, the approved antiplatelet products include aspirin and thienopyridines, such as clopidogrel and ticlopidine. One of the most widely prescribed thienopyridines is clopidogrel, which is also known as Plavix®.\n\nTheinopyridines such as clopidogrel irreversibly inhibit P2Y 12 receptors, which play an active role in platelet activation. In the normal state, where blood vessels are damaged, platelet activation mediated by P2Y 12 receptors play an important role to arrest bleeding at the site of injury. In a diseased state, platelet activation leads to vascular occlusion and ischemic damage. Thus, P2Y 12 receptor antagonists play a key role in antiplatelet therapy in assisting to prevent coronary artery disease and for the immediate treatment of ACS and percutaneous coronary intervention (PCI).\n\nPhysicians often prescribe dual antiplatelet therapy, which include aspirin and a thienopyridine such as clopidogrel, as a first line treatment for patients who have been diagnosed with ACS or who are showing symptoms associated with ACS. Pending further examinations, these patients may continue with this treatment or receive other treatments such as coronary artery bypass grafting (CABG) and PCI.",
  "cpc": [
    "A61K 31/7076",
    "A61K 2300/00",
    "A61K 31/00",
    "A61K 31/4365",
    "A61K 9/0019",
    "A61P 43/00",
    "A61P 7/02",
    "A61P 9/00",
    "A61P 9/10"
  ],
  "ipc": [
    "A61K 31/7076",
    "A61K 9/00",
    "A01N 43/04",
    "A61K 31/00",
    "A61K 31/4365",
    "A61K 31/70"
  ],
  "assignees": [
    "Chiesi Farmaceutici SpA"
  ],
  "inventors": [
    "Lisa Ruderman Chen",
    "Simona Skerjanec",
    "Dawn Bell",
    "Jayne Prats",
    "Meredith Todd"
  ],
  "filing_date": "2016-04-24",
  "publication_date": "2018-07-17",
  "grant_date": "2018-07-17",
  "priority_date": "2008-05-13",
  "application_number": "US-201615136979-A",
  "family_id": "41319000",
  "cited_by_count": 249,
  "citations": [
    "US4529596A",
    "US5256559A",
    "US5288726A",
    "US5721219A",
    "US5955447A",
    "US6114313A",
    "US6130208A",
    "US20060270607A1",
    "US6693115B2",
    "US6861424B2",
    "US20110081657A1",
    "US20060121086A1",
    "US20070082840A1",
    "US20100041587A1",
    "US20070254324A1",
    "US20090247465A1",
    "US20130324492A1",
    "US20130303477A1",
    "US9320754B2",
    "US20150038449A1",
    "US20110288043A1",
    "US20120141468A1",
    "US8871736B2",
    "US8759316B2",
    "US20130303478A1",
    "WO2009140092A1",
    "US20130316968A1",
    "WO2009140407A1",
    "US8716261B2",
    "US20140107032A1",
    "US20130190265A1",
    "WO2011060066A2",
    "US20110112030A1",
    "US9427448B2",
    "US20130040898A1",
    "US8680052B1"
  ]
}